Does MK-801 discrimination constitute an animal model of schizophrenia useful for detecting atypical antipsychotics?

Pharmacology Biochemistry and Behavior

Volumn 64, Issue 2, 1999, Pages 429-433

  Smith, Judith A ^a   Boyer Millar, Charlotte ^a   Goudie, Andrew J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Atypical antipsychotics; Clozapine; Drug discrimination; MK 801; NMDA antagonism; Perceptual masking; Prazosin; Psychotomimetic

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DIZOCILPINE; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PRAZOSIN;

ANIMAL EXPERIMENT; CONFERENCE PAPER; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DRUG ANTAGONISM; DRUG DISCRIMINATION; FEMALE; INSTRUMENTAL CONDITIONING; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; TRAINING;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; CUES; DISCRIMINATION (PSYCHOLOGY); DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; PRAZOSIN; RATS; RATS, WISTAR; REINFORCEMENT SCHEDULE; REWARD; SCHIZOPHRENIA;

ANIMALIA; RATTUS NORVEGICUS;

EID: 0032820266     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(99)00077-5     Document Type: Conference Paper

References (29)

1. Arnt J., Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology. 18:1998;63-101.
2. Balster, R. L.: Behavioral pharmacology of PCP, NMDA and sigma receptors. 51st Annual Meeting of the Committee on Problems of Drug Dependence (1989, Keystone, CO). Natl. Inst. Drug Abuse Res. Monogr. Series 95:270-274; 1989.
3. Contreras P.C., Monahan J.B., Lanthorn T.H., Pullan L.M., DiMaggio D.A., Handelman G.E., Gray N.M., O'Donohue T.L. Phencyclidine. Physiological actions, interactions with excitatory amino acids and endogenous ligands Mol. Neurobiol. 1:1987;191.
4. Corbett R. Clozapine but not haloperidol antagonizes an MK-801 discriminative stimulus cue. Pharmacol. Biochem. Behav. 51:1995;561-564.
5. Corbett R., Camacho F., Woods A.T., Kerman L.L., Fishkin R.J., Brooks K., Dunn R.W. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology (Berlin). 120:1995;67-74.
6. Farber N.B., Price M.T., Labruyere J., Nemnich J., St. Peter H., Wozniak D.F., Olney J.W. Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity. Biol. Psychiatry. 34:1993;119-121.
7. Franklin S.R., Tang A.H. Discriminative stimulus effects of clozapine in rats. Behav. Pharmacol. 5:1994;113-114.
8. Gauvin D.V., Peirce J.M., Holloway F.A. Perceptual masking of the chlordiazepoxide discriminative cue by both caffeine and buspirone. Pharmacol. Biochem. Behav. 47:1994;153-159.
9. Goudie A., Taylor A. Comparative characteristics of the discriminative stimulus properties of clozapine and other antipsychotics in rats. Psychopharmacology (Berlin). 135:1998;392-400.
10. Hoffman D.C. Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J. Neural Transm. 89:1992;1-10.
11. Jentsch J.D., Redmond D.E., Elsworth J.D., Taylor J.R., Youngren K.D., Roth R.H. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science. 277:1997;953-955.
12. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine Arch. Gen. Psychiatry. 45:1988;789-796.
13. Kim J., Kornhuber H., Scmid-Burgk W., Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20:1980;379-382.
14. Koek W., Kleven M.S., Colpaert F.C. Effects of the NMDA antagonist, dizocilpine, in various drug discriminations. Characterization of intermediate levels of drug lever selection Behav. Pharmacol. 6:1995;590-600.
15. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 13:1995;9-19.
16. Luby E., Cohen B., Rosenbaum F., Gottleib J., Kelly R. Study of a new schizophrenomimetic drug, Sernyl. Arch. Neurol. Psychiatry. 81:1959;363-369.
17. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology. 17:1997;141-150.
18. Mathé J.M., Nomikos G.G., Hildebrand B.E., Hertel P., Svensson T.H. Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. Eur. J. Pharmacol. 309:1996;1-11.
19. Nielsen E.B. Cholinergic mediation of the discriminative stimulus properties of clozapine. Psychopharmacology (Berlin). 94:1988;115-118.
20. Perry T. Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction. Neurosci. Lett. 28:1982;81-85.
21. Sams-Dodd F. Phencyclidine-induced stereotyped behaviour and social isolation in rats. A possible animal model of schizophrenia Behav. Pharmacol. 7:1996;3-23.
22. Sanger, D. J.: Personal communication; 1996.
23. Sanger D.J., Zivkovic B. The discriminative stimulus effects of MK-801. Generalisation to other N-methyl-D-aspartate receptor antagonists J. Psychopharmacol. 3:1989;198-204.
24. Swerdlow N.R., Bakshi V., Geyer M.A. Seroquel restores sensorimotor gating in phencyclidine-treated rats. J. Pharmacol. Exp. Ther. 279:1996;1290-1299.
25. Tiedtke P., Bischoff C., Schmidt W.J. MK-801-induced stereotypy and its antagonism by neuroleptic drugs. J. Neural Transm. 81:1990;173-182.
26. Tsai G., Passani L., Slusher B. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiatry. 52:1995;829-836.
27. Waters N., Lundgren C, Hansson L.O., Carlsson M.L. Concurrent locomotor stimulation and decrease in dopamine release in rats and mice after treatment with the competitive NMDA receptor antagonists D-CPPene and CGS 19755. J. Neural Transm. 103:1996;117-129.
28. Wedzony K., Golembiowska K., Zazula M. Differential effects of CGP 37849 and MK-801, competitive and noncompetitive NMDA antagonists, with respect to the modulation of sensorimotor gating and dopamine outflow in the prefrontal cortex of rats. Naunyn Schmeidebergs Arch. Pharmacol. 350:1994;555-562.
29. Willets J., Balster R., Leander J. The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol. Sci. 11:1990;423-428.